Science1 publisherNot yet confirmed elsewhere3 min readPublished
EPA clears spinach-peptide graft therapy for citrus greening, with no tolerance limit
Silvec Biologics holds unconditional FIFRA registration for a spinach defensin therapy delivered by grafting. Efficacy numbers, price and throughput are not in the announcement.
The Scientist · Science desk
Drafted by a language model from the sources cited here and checked against its claim ledger before publication. How we use AISend a correction
What happened
- The U.S. Environmental Protection Agency has granted unconditional registration to a novel citrus greening disease therapy rooted in more than a decade of research at Texas A&M AgriLife Research.
- The product is registered by Maryland-based Silvec Biologics Inc.
- The EPA registration is issued under the Federal Insecticide, Fungicide and Rodenticide Act and allows the spinach defensin-based therapy product to be sold commercially without a tolerance limit, a designation reflecting years of safety data gathered through the research partnership.
- Mandadi and his research team demonstrated that naturally occurring antimicrobial peptides from spinach, known as defensins, can protect citrus trees from Huanglongbing, known as citrus greening.
- The article describes citrus greening as one of the most destructive diseases in modern agriculture.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
The Environmental Protection Agency has granted unconditional registration to a citrus greening therapy built on antimicrobial peptides from spinach, with Maryland-based Silvec Biologics Inc. as the registrant [1][2]. The registration is issued under the Federal Insecticide, Fungicide and Rodenticide Act and allows the product to be sold commercially without a tolerance limit, a designation that Texas A&M AgriLife Research attributes to years of safety data gathered through the research partnership [3].
The underlying finding is that naturally occurring spinach defensins can protect citrus trees from Huanglongbing, which the announcement calls one of the most destructive diseases in modern agriculture [14][4]. The work was led by Kranthi Mandadi at the Texas A&M AgriLife Research and Extension Center at Weslaco, with Bill Dawson, emeritus professor at the University of Florida, and Choaa El-Mohtar, a research scientist at the Citrus Research and Education Center [7][8]. Mandadi's line of work started with Erik Mirkov, an AgriLife Research plant pathologist at Weslaco, and the pair identified the defensin peptides as a possible treatment [9]. The full effort ran about 15 years across multiple public and private institutions [10].
The delivery method is the part growers will have to plan around. According to Mike Irey, director of research at Southern Gardens Citrus in Clewiston, Florida, the product uses a naturally non-transmissible strain of citrus tristeza virus already common in Florida citrus, reprogrammed to prompt the tree to produce the spinach defensin [11]. The approach, developed by Dawson's team, does not alter the tree's genome and works by grafting a small piece of plant material from a specially developed source tree onto an existing tree [12][13]. Once the benign CTV is established, it continues producing the defensin, which the announcement says helps fight the bacteria associated with citrus greening [15]. That is a per-tree operation, not a tank mix, so the constraint on deployment is grafting labor and source-tree supply rather than sprayer passes.
The intellectual property is split and stacked. The defensin is patented by The Texas A&M University System and the CTV delivery technology by the University of Florida; both are licensed to Southern Gardens Citrus, which funded the sponsored research leading to registration, and both were sublicensed to Silvec to obtain the registration and commercialize the treatment [5][6].
What the announcement does not contain is the operator's decision data: no efficacy figures, no price, no application-rate or grafting-throughput numbers, and no statement of how long expression persists in the field. Mandadi's own framing of the no-tolerance-limit designation is that it is a testament to safety, not to performance [16]. Dale Murden, president of Texas Citrus Mutual, likewise stayed conditional, saying growers "will have new, sustainable treatments that could keep citrus trees productive under disease pressure" [17]. Cliff Lamb, director of AgriLife Research, cast the milestone as a return on long-term public investment in commercialization [18].
Watch for the first commercial availability, which Silvec expects to begin with Florida growers [19], and for the specifics that follow a registration into the market: labeled use directions, per-tree cost, and independent field data on how much yield or tree life a graft actually buys.